Rashed Ebrahim, Soldera Jonathan
Acute Medicine, University of South Wales, Cardiff CF37 1DL, United Kingdom.
World J Hepatol. 2022 Dec 27;14(12):2025-2043. doi: 10.4254/wjh.v14.i12.2025.
Acute-on-chronic liver failure (ACLF) is a syndrome characterized by decompensation in individuals with chronic liver disease, generally secondary to one or more extra-hepatic organ failures, implying an elevated mortality rate. Acute decompensation (AD) is the term used for one or more significant consequences of liver disease in a short time and is the most common reason for hospital admission in cirrhotic patients. The European Association for the Study of Liver-Chronic-Liver Failure (EASL-CLIF) Group modified the intensive care Sequential Organ Failure Assessment score into CLIF-SOFA, which detects the presence of ACLF in patients with or without AD, classifying it into three grades
To investigate the role of the EASL-CLIF definition for ACLF and the ability of CLIF-SOFA, CLIF-C ACLF, and CLIF-C AD scores for prognosticating ACLF or AD.
This study is a literature review using a standardized search method, conducted using the steps following the guidelines for reporting systematic reviews set out by the PRISMA statement. For specific keywords, relevant articles were found by searching PubMed, ScienceDirect, and BioMed Central-BMC. The databases were searched using the search terms by one reviewer, and a list of potentially eligible studies was generated based on the titles and abstracts screened. The data were then extracted and assessed on the basis of the Reference Citation Analysis (https://www.referencecitationanalysis.com/).
Most of the included studies used the EASL-CLIF definition for ACLF to identify cirrhotic patients with a significant risk of short-term mortality. The primary outcome in all reviewed studies was mortality. Most of the study findings were based on an area under the receiver operating characteristic curve (AUROC) analysis, which revealed that CLIF-SOFA, CLIF-C ACLF, and CLIF-C AD scores were preferable to other models predicting 28-d mortality. Their AUROC scores were higher and able to predict all-cause mortality at 90, 180, and 365 d. A total of 50 articles were included in this study, which found that the CLIF-SOFA, CLIF-C ACLF and CLIF-C AD scores in more than half of the articles were able to predict short-term and long-term mortality in patients with either ACLF or AD.
CLIF-SOFA score surpasses other models in predicting mortality in ACLF patients, especially in the short-term. CLIF-SOFA, CLIF-C ACLF, and CLIF-C AD are accurate short-term and long-term mortality prognosticating scores.
慢加急性肝衰竭(ACLF)是一种以慢性肝病患者失代偿为特征的综合征,通常继发于一个或多个肝外器官衰竭,意味着死亡率升高。急性失代偿(AD)是指在短时间内肝病出现的一种或多种严重后果,是肝硬化患者住院的最常见原因。欧洲肝脏研究学会-慢性肝衰竭(EASL-CLIF)小组将重症监护序贯器官衰竭评估评分修改为CLIF-SOFA,用于检测有无AD的患者中ACLF的存在,并将其分为三个等级。
探讨EASL-CLIF对ACLF的定义作用以及CLIF-SOFA、CLIF-C ACLF和CLIF-C AD评分对ACLF或AD进行预后评估的能力。
本研究是一项采用标准化检索方法的文献综述,按照PRISMA声明中报告系统评价的指南步骤进行。对于特定关键词,通过检索PubMed、ScienceDirect和BioMed Central-BMC查找相关文章。由一名评审员使用检索词对数据库进行检索,并根据筛选的标题和摘要生成一份潜在合格研究列表。然后根据参考文献引用分析(https://www.referencecitationanalysis.com/)对数据进行提取和评估。
大多数纳入研究使用EASL-CLIF对ACLF的定义来识别有短期死亡重大风险的肝硬化患者。所有综述研究的主要结局是死亡率。大多数研究结果基于受试者工作特征曲线下面积(AUROC)分析,该分析表明CLIF-SOFA、CLIF-C ACLF和CLIF-C AD评分优于其他预测28天死亡率的模型。它们的AUROC评分更高,能够预测90天、180天和365天的全因死亡率。本研究共纳入50篇文章,发现超过半数文章中的CLIF-SOFA、CLIF-C ACLF和CLIF-C AD评分能够预测ACLF或AD患者的短期和长期死亡率。
CLIF-SOFA评分在预测ACLF患者死亡率方面优于其他模型,尤其是在短期内。CLIF-SOFA、CLIF-C ACLF和CLIF-C AD是准确的短期和长期死亡率预后评估评分。